Tafamidis meglumine

Tafamidis meglumine
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 330120

CAS#: 951395-08-7 (meglumine)

Description: Tafamidis, also known as Fx-1006 or PF-06291826, is a drug for the amelioration of transthyretin-related hereditary amyloidosis (also familial amyloid polyneuropathy, or FAP), a rare but deadly neurodegenerative disease. The drug was approved by the European Medicines Agency in November 2011 and by the Japanese Pharmaceuticals and Medical Devices Agency in September 2013. Tafamidis functions by kinetic stabilization of the correctly folded tetrameric form of the transthyretin (TTR) protein.

Chemical Structure

Tafamidis meglumine

CAS# 951395-08-7 (meglumine)

Instruction

Theoretical Analysis

MedKoo Cat#: 330120
Name: Tafamidis meglumine
CAS#: 951395-08-7 (meglumine)
Chemical Formula: C21H24Cl2N2O8
Exact Mass: 502.09
Molecular Weight: 503.329
Elemental Analysis: C, 50.11; H, 4.81; Cl, 14.09; N, 5.57; O, 25.43

Price and Availability

Size	Price	Availability
50mg	USD 250	2 Weeks
100mg	USD 450	2 Weeks
200mg	USD 750	2 Weeks
500mg	USD 1350	2 Weeks
1g	USD 2350	2 Weeks
2g	USD 3950	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Related CAS #: 594839-88-0 (free acid) 951395-08-7 (meglumine)

Synonym: Tafamidis meglumine; Fx 1006A; Fx-1006A; Fx1006A; PF-06291826; PF 06291826; PF06291826;

IUPAC/Chemical Name: (2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentaol 2-(3,5-dichlorophenyl)benzo[d]oxazole-6-carboxylic acid

InChi Key: DQJDBUPLRMRBAB-WZTVWXICSA-N

InChi Code: InChI=1S/C14H7Cl2NO3.C7H17NO5/c15-9-3-8(4-10(16)6-9)13-17-11-2-1-7(14(18)19)5-12(11)20-13;1-8-2-4(10)6(12)7(13)5(11)3-9/h1-6H,(H,18,19);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1

SMILES Code: OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CNC.O=C(C1=CC=C2N=C(C3=CC(Cl)=CC(Cl)=C3)OC2=C1)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 503.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Cruz MW. Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review. Clin Auton Res. 2019 Sep;29(Suppl 1):19-24. doi: 10.1007/s10286-019-00625-9. Epub 2019 Aug 12. Review. PubMed PMID: 31407119; PubMed Central PMCID: PMC6763524.

2: Lamb YN, Deeks ED. Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy. Drugs. 2019 Jun;79(8):863-874. doi: 10.1007/s40265-019-01129-6. Review. PubMed PMID: 31098895.

3: Lorenzini M, Elliott PM. Tafamidis for the treatment of transthyretin amyloidosis. Future Cardiol. 2019 Mar;15(2):53-61. doi: 10.2217/fca-2018-0078. Epub 2019 Feb 15. Review. PubMed PMID: 30767672.

4: Planté-Bordeneuve V, Lin H, Gollob J, Agarwal S, Betts M, Fahrbach K, Chitnis M, Polydefkis M. An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy. Expert Opin Pharmacother. 2019 Mar;20(4):473-481. doi: 10.1080/14656566.2018.1554648. Epub 2018 Dec 12. Review. PubMed PMID: 30489166.

5: Maurer MS, Elliott P, Merlini G, Shah SJ, Cruz MW, Flynn A, Gundapaneni B, Hahn C, Riley S, Schwartz J, Sultan MB, Rapezzi C; ATTR-ACT Study Investigators. Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). Circ Heart Fail. 2017 Jun;10(6). pii: e003815. doi: 10.1161/CIRCHEARTFAILURE.116.003815. Review. PubMed PMID: 28611125.

6: Institute for Quality and Efficiency in Health Care. Tafamidis Meglumine -- Benefit Assessment According to §35a Social Code Book V [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2012 Mar 13. Available from http://www.ncbi.nlm.nih.gov/books/NBK385651/ PubMed PMID: 27905733.

7: Coelho T, Merlini G, Bulawa CE, Fleming JA, Judge DP, Kelly JW, Maurer MS, Planté-Bordeneuve V, Labaudinière R, Mundayat R, Riley S, Lombardo I, Huertas P. Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. Neurol Ther. 2016 Jun;5(1):1-25. doi: 10.1007/s40120-016-0040-x. Epub 2016 Feb 19. Review. PubMed PMID: 26894299; PubMed Central PMCID: PMC4919130.

8: Scott LJ. Tafamidis: a review of its use in familial amyloid polyneuropathy. Drugs. 2014 Aug;74(12):1371-8. doi: 10.1007/s40265-014-0260-2. Review. PubMed PMID: 25022953.

9: Buxbaum JN. Evaluation of tafamidis as first-line therapeutic agent for transthyretin familial amyloidotic polyneuropathy. Degener Neurol Neuromuscul Dis. 2012 Oct 19;2:165-173. doi: 10.2147/DNND.S24624. eCollection 2012. Review. PubMed PMID: 30890886; PubMed Central PMCID: PMC6065585.

10: de Lartigue J. Tafamidis for transthyretin amyloidosis. Drugs Today (Barc). 2012 May;48(5):331-7. doi: 10.1358/dot.2012.48.5.1808486. Review. PubMed PMID: 22645721.

Your view history